Anthony Mato, MD, shares findings from a phase I/II trial evaluating LOXO-305 in patients with heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Skip Nav Destination
![]()
![]()
Anthony Mato: LOXO-305 Demonstrates Efficacy in Patients With CLL/SLL
December 30, 2021
Connect with us:
CURRENT ISSUE
October 2024
